<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352896</url>
  </required_header>
  <id_info>
    <org_study_id>EPI743-13-023</org_study_id>
    <nct_id>NCT02352896</nct_id>
  </id_info>
  <brief_title>Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome</brief_title>
  <official_title>Long-Term Safety and Efficacy Evaluation of Vatiquinone (EPI-743) in Children With Leigh Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002
      (NCT01721733) study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To monitor the long-term safety and neurodevelopmental effects of EPI-743 on children who
      complete the EPI743-12-002 placebo-controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Severity as Measured by Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3 Score</measure>
    <time_frame>Baseline up to Month 36</time_frame>
    <description>NPMDS is a validated scale to assess the mitochondrial disease progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Dose-Limiting Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Month 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bayley Scales of Infant Development-III Score (Participants Age 0-3)</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>Effect of EPI-743 on neurodevelopment will be measured by Bayley Scales of Infant Development-III score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wechsler Scale of Intelligence and Movement Assessment Battery Score for Children (Participants Age 4-18)</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>Effect of EPI-743 on neuromuscular function will be assessed by Wechsler Scale of Intelligence and Movement Assessment Battery score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barry-Albright Dystonia Scale Score</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>Neuromuscular function will be assessed by Barry-Albright Dystonia Scale score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gross Motor Function Measure</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>Neuromuscular function will be assessed by gross motor function measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Awake Oxygen Saturation Levels</measure>
    <time_frame>Baseline up to Month 24</time_frame>
    <description>Effect of EPI-743 on respiratory function will be measured by awake oxygen saturation levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Ventilator Days and Total Intensive Care Unit Days</measure>
    <time_frame>Baseline up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pneumonia Episodes and Tracheostomy</measure>
    <time_frame>Baseline up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Mortalities, Medical Encounters, Hospitalizations, and Hospital Days</measure>
    <time_frame>Baseline up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life as Measured by NPMDS Section 4 Score</measure>
    <time_frame>Baseline up to Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione Cycle Biomarkers Level</measure>
    <time_frame>Baseline up to Month 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Leigh Syndrome</condition>
  <arm_group>
    <arm_group_label>EPI-743</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive EPI-743 at a dose of 15 milligrams/kilogram (mg/kg) up to a total 200 mg 3 times daily (TID) orally with meal or by using nasogastric (NG) or gastrostomy feeding tubes with liquid food for at least 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743</intervention_name>
    <description>EPI-743 100 milligrams/milliliter (mg/mL) oral solution will be administered per dose and schedule specified in the arm.</description>
    <arm_group_label>EPI-743</arm_group_label>
    <other_name>Vincerinone, Vatiquinone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Leigh syndrome with genetic confirmation

          2. Completion of EPI743-12-002 protocol and initiation of treatment within 14 days of
             Month 12 visit in EPI743-12-002 study

          3. Participant or participant's guardian able to consent and comply with protocol
             requirements

          4. Continued abstention from supplements excluded in EPI743-12-002 study

          5. BotoxÂ® is allowed if approved by the sponsor

        Exclusion Criteria:

          1. Allergy to EPI-743 or sesame oil

          2. Allergy to vitamin E

          3. Clinical history of bleeding or abnormal baseline prothrombin time (PT)/partial
             thromboplastin time (PTT)

          4. Hepatic insufficiency with liver function tests (LFTs) greater than two times upper
             limit of normal

          5. Renal insufficiency requiring dialysis

          6. End-stage cardiac failure

          7. Fat malabsorption syndromes precluding drug absorption

          8. Use of anticoagulant medications

          9. Participation in other clinical research studies/taking other experimental agents

         10. Participation in elective procedures that required sedation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akron Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gregory Enns</name>
      <address>
        <city>Stanford University</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leigh syndrome</keyword>
  <keyword>Mitochondrial disorders</keyword>
  <keyword>EPI743</keyword>
  <keyword>Vincerinone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leigh Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

